Remission in Dystonia – systematic review of the literature and meta-analysis *(max 100 characters)*

Tina Mainka[1], Roberto Erro[2], John Rothwell[3], Andrea A. Kühn[1], Kailash P. Bhatia[3] and Christos Ganos[1]

[1]Department of Neurology, Charité University Medicine Berlin, Berlin, Germany

[2]Department of Neurosciences, Biomedicine and Movement sciences, Università di Verona, Verona, Italy

[3]Sobell Department of Motor Neuroscience and Movement Disorders, University College London Institute of Neurology, University College London, London, UK

Corresponding Author:

Dr. med. Christos Ganos, Department of Neurology, Charité University Medicine Berlin, Charitéplatz 1, 10117 Berlin, Germany, eMail: christos.ganos@charite.de

Word count

xxx

Running title *(max 45 characters)*

Remission in Dystonia

Key words

Remission, Dystonia, Recovery

Abstract

In isolated, sporadic dystonia, it has been occasionally reported that some patients might undergo symptom remission. However, the exact clinical characteristics of patients with remission remain understudied. Given the important prognostic and pathophysiological implications of dystonic remission, we here provide a systematic review of the literature and a meta-analysis to assess demographic and clinical features associated with this phenomenon. We also provide a list of operational criteria to better define dystonic remission. Using PubMed and Embase, we conducted a systematic literature search in March 2018. 626 records were screened, 31 studies comprising data of 2551 patients with predominantly reports from patients with cervical dystonia (n=1319) or blepharospasm/Meige syndrome (n=704) were included in qualitative analysis. Five studies reporting remission in cervical dystonia were eligible for meta-analysis. Complete remission was reported in 11.8% and partial remission for 4.4% of cases. Remission rates were higher in cervical dystonia than in blepharospasm/Meige (e.g. complete remission 15.4% vs. 5.8% respectively). Remission occurred on average 4.5 years after onset of dystonic symptoms. However, the majority of patients (63.8%) relapsed. Meta-analysis for cervical dystonia showed that patients with remission were significantly younger at symptom onset than patients without remission (mean difference -7.13 years [95% CI: -10.58 – -3.68], p<0.0001). Based on our findings, we propose that the *degree*, the conditions associated with the *onset* and the *duration* of remission are key factors to be considered in a unifying definition of dystonic remission.

Introduction

Dystonia is a movement disorder characterized by abnormal movements and/ or postures due to involuntary muscle contractions (Albanese, 2013)(1). Dystonia has a wide range of etiologies and often co-occurs with additional clinical signs (combined or complex dystonia) in the context of neurodegenerative disorders (Fung, 2013)(2) or as a result of brain lesions (Kojovic, 2013, Bhatia, 1994)(3,4). Isolated dystonia refers to cases where beyond the presence of dystonia (with or without concomitant tremor) there is nothing else(1). In familial cases of isolated dystonia, several genes have now been identified (Lohmann, 2017)(5) and genotypic-phenotypic correlations have provided important information on long-term prognosis. However, in sporadic isolated dystonia – in the old literature also referred to as "primary" dystonia – relatively little progress has been made. These cases are classified based on the distribution of dystonic symptoms at onset, but very little is known with regard to prognosis, as for example their severity progression or somatotopic spread (Martino, 2012, Defazio, 1999, LeDoux, 2016)(6–8). It has been occasionally reported that some patients with isolated sporadic dystonia might experience symptom remission, but this has not been systematically assessed. In an era where treatment options expand beyond oral medication or botulinum toxin injections and also entail surgical interventions, the possibility of sustained remission has very important implications. Knowing which patients might undergo sustained remission could, therefore, be crucial for patient counselling and appropriate treatment selection. Hence, to provide a clear overview of the existing reports on dystonic remission, we here conducted a systematic review of the literature. We also aimed to perform a meta-analytic study, in order to specifically address whether some demographic and clinical features are more prevalent or are associated with dystonic remission.

Methods

In March 2018, we conducted a systematic literature search in PubMed (http://www.ncbi.nlm.nih.gov) and Embase (https://www.elsevier.com/solutions/embase-biomedical-research) using the keywords "dystonia", "dystonic", "cervical dystonia", "torticollis", "blepharospasm", "Meige", "cranial dystonia" and "writer's cramp" in combination with the keywords "remission/s", "recovery" and "cure", respectively. Additionally, the bibliographies of relevant articles were scanned for further suitable literature. We considered only articles containing data of original clinical studies in English and German language. Duplicate articles, reviews, and opinions/ comments were excluded. We screened the abstracts and full texts, if available, for relevant information, which was then systematically entered into a comprehensive table. We excluded case reports to avoid overestimation of remission. Articles referring to acquired causes of dystonia (e.g., due to brain lesions), as well as studies in which surgical interventions, as for example myotomy or deep brain stimulation, were performed, were also not considered. Cases of improvement due to medication, characteristically in dopamine-responsive dystonia, or due to direct effects of botulinum toxin (i.e. improvement with ongoing botulinum toxin injection treatment) were also excluded. Additionally, we excluded reports of

fixed dystonia that might be associated with a different underlying etiology and tardive dystonic syndromes (see figure 1). The review was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement (Moher, 2009) (9).

We classified remission as complete in cases in which a full resolution of dystonic symptoms was reported regardless of its duration or a subsequent recurrence of dystonic symptoms. Partial remission was considered in all other cases in which improvement, but not complete resolution of symptoms was stated (e.g., "substantial recovery", "much/ moderate/ slight improvement"). Since some studies used either validated scales for the evaluation of dystonic symptoms or subjective data (e.g. patient reports) or both, we used objective measures where possible.

Further, studies were selected for meta-analysis, if they involved a comparison between patients with and without remission (e.g. gender specification, age at onset of the disease, disease duration) and exact numbers of patients could be categorized, and where means and standard deviations were given or could be calculated from the reported data. Eventually, 5 studies reporting remission in patients with CD fulfilled these criteria, the data of which were pooled into a random-effects model with regard of age at onset and disease duration, in line with the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0)(10). We additionally undertook consideration of all the included studies in the pooled analysis to estimate clinical heterogeneity. This was done employing, primarily, the I^2 statistic, which provides an estimate of the percentage of inconsistency thought to be due to chance, alongside the Chi-2 p value that provides the strength of evidence for heterogeneity. The latter analyses were performed with RevMan, version 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. These results are indicated as standardized mean difference (SMD) with 95% confidence intervals (CIs). Categorical data was compared using chi-square-tests. Level of significance was set at $p < 0.05$.

Results

In total, 626 articles were identified (see supplement 1). After the screening process, 31 articles comprising data of 2551 patients were included in the final analyses. The majority of reported cases referred to cervical dystonia (CD; n = 1319, 51.7%), followed by either blepharospasm (BSP) or Meige syndrome (n = 704, 27.6%). Phenotypic classification of 481 (18.9%) patients was not possible, due to insufficient clinical data. A complete list of reported phenotypes and their frequencies is provided in table 1.

A clear definition of remission was provided in only 8 of 31 studies (25.8%). Among these, 4 studies defined remission as a significant improvement occurring in the absence of any treatment (Giladi, 2000, Friedman, 1986, Pal, 2000, Jahanshahi, 1990) (11–14)and four studies required a minimum duration of symptom improvement of 1 year to allocate patients in the remission group (Giladi, 2000,

Friedman, 1986, Meares, 1971, Koukouni, 2007) (11,12,15,16). In the majority of studies (n = 27/ 31) remission was evaluated by physicians.

Overall, complete remission (CR) was reported for 301 (11.8%) and partial remission (PR) for 113 (4.4%) of identified cases. In patients with CD, remission rates were approximately threefold higher than in patients with BSP and Meige syndrome (CD: CR 15.4%, PR 7.4% vs. BSP/ Meige syndrome: CR 5.8%, no PR). In generalized dystonia remission rate was 23.8%, however we could only collect data from a single case series (Marsden, 1974)(17). No remissions were reported in patients with embouchure dystonia (see table 2). The mean age of disease onset in patients with remission was lower than the age of onset in the whole group (34.8 vs. 42 years). On average, remission was reported to occur 4.5 years (3 months – 22 years) after the onset of the disease.

Dystonic relapse was assessed in only eleven studies, which reported remission. In total data from 163 patients undergoing remission was available. Of those, relapse was reported in 63.8% (n = 104) and ranged from 58.7% in CD to 100% in generalized dystonia (Bradley, 2003, Lowenstein and Aminoff, 1988, Paterson, 1945, Herz and Glaser, 1949, Matthews, 1978, Marsden, 1974, Jahanshahi, 1990, Friedman and Fahn, 1986, Chan, 1991, Koukouni, 2007, Grandas, 1988)(12,14,16–24). Remission duration (either to relapse or last follow-up) was shorter in patients with CD (2.7 years) than in patients with BSP and Meige syndrome (7.1 years). (see table 2).

Meta-analysis showed that the age of onset in patients with CD and remission was significantly lower than in patients without remission (mean difference -7.13 years [95% CI: -10.58 – -3.68], p < 0.0001, see fig. 2a). There was no significant heterogeneity among the included studies [$I^2 = 8\%$, p = 0.36]. There was no significant difference in disease duration between patients with CD and remission and those without remission (mean difference 2.75 years [95% CI: -0.48 – 5.97], p = 0.09, see fig. 2b). Gender distribution also did not differ between the two groups (remission: 38 males, 63 females, non-remission: 171 males, 267 females, p = 0.792).

Discussion

In our reviewed sample of 2551 patients with dystonia, remission was reported in 16.2% of cases. Among the focal dystonias, rate of reported remissions was higher in CD (22.8%), than in BSP or Meige syndrome (5.8%). There were no systematic reports of remission in task specific dystonias, such as focal hand dystonia and in fact, a single study, which assessed remissions in embouchure dystonia found no such cases (Frucht, 2001)(25). To some extent, the high prevalence of remission rates in CD reflects the overall prevalence of CD, as it is the most common form of focal dystonia (26–28)(Steeves, 2012, Williams, 2017, Defazio, 2017). However, prevalence alone cannot account for the threefold increase of remission rate in CD compared to BSP/ Meige syndrome, which is the next most commonly reported phenotype (26–28)(Steeves, 2012, Williams, 2017, Defazio, 2017). Therefore, additional factors contribute to the increased likelihood of remission in CD compared to

other isolated dystonias. Indeed, based on our meta-analysis, CD patients with remission were younger at symptom onset than patients without remission (average of 7.1 years). Although, the exact effect of age as a phenotypic modifier of CD remains underexplored, previous data suggested that age at onset of CD is associated with different expression of dystonic symptoms(29)(Norris, 2016). Patients who were younger at the manifestation of CD had more focal presentations compared to patients with older age at onset, where widespread dystonic symptoms (i.e. segmental dystonia) prevailed(29) (Norris, 2016). On one account, the somatotopic extent of dystonic symptoms also serves as a behavioural marker of the magnitude of neuronal deficits leading to dystonia (Kroneberg, 2017, Meunier, 2001, Berman, 2018) (30–32). Accordingly, the more restricted forms of CD would also be associated with more confined neuronal deficits and, thereby, increased likelihood of compensatory changes (33,34)(Draganski, 2009, Sadnicka, 2012) to occur that could lead to symptom remission. In contrast, patients with more widespread patterns of dystonic symptoms, as those with older age at onset and segmental dystonia (29), would have a lesser probability of neural compensation and, thereby, remission. A key prediction of this approach is that the overall likelihood of remission for the different dystonic phenotypes depends on the magnitude of the underlying neural deficits. Indeed, our results do seem to support the simple analogy between the number of neurons involved in the cortico-subcortical sensorimotor representations for the different body areas (e.g. neck versus face) and the probability of remission for the different dystonic phenotypes (CD > BSP/ Meige). The lack of unequivocal reports on remission in other focal dystonias, as for example task-specific dystonias (e.g. focal hand/ musicians' and embouchure dystonia) and the single case series on generalized dystonia mean that we cannot further explore this hypothesis.

The suggestion that remission is influenced by the extent of the dystonic deficit is also corroborated by the finding that the time period, during which remission occurred, was on average within the first 5 years of the disorder. Importantly, this was true for both CD (mean 4.5 years) and BSP/ Meige syndrome (mean 4.4 years) (no data available for generalized dystonia; see table 2). Indeed, this initial period after symptom onset is critical, as it provides the time frame during which dystonic spreads to contiguous body parts, particularly in BSP (7,35)(Abbruzzese, 2008, Martino, 2012). According to our hypothesis here, patients at incipient risk of dystonic spread would have a lesser probability to undergo remission.

From a pathophysiological perspective, changes in somatosensory processing of stimuli and sensorimotor integration are key findings in focal dystonia, including CD (36,37)(Avanzino, 2015, Ganos, 2017). Crucially, processing and integration of somatosensory stimuli are age-dependent functions that decline in elder populations (38–40)(Skinner, 1984, Ingemanson, 2016, Ramos, 2016). One might, therefore, argue, that with increasing age, the capacity to provide accurate computations of somatosensory input and sensorimotor integration is reduced. This, in turn, could also decrease the probability of symptom compensation associated with clinical remission in dystonia, as for example

CD. This pathophysiological approach also highlights the role of sensory tricks, which are particularly prevalent in CD(41) (Ramos, 2014). Evidently, sensory tricks lead to a temporary improvement of dystonic symptoms and could be, therefore, viewed as a reflection of the capacity to gain behavioural control over pathological motor output (41) (Ramos, 2014). Somewhat, counterintuitively, therefore, one paper suggested that absent sensory tricks in CD patients would be associated with increased likelihood of remission (19)(Lowenstein, 1988). However, the exact phenomenology of CD (focal or segmental) was not well defined in this study and subsequent reports did not further replicate this finding (Jahanshahi, 1990; Koukouni, 2007) (14,16). In the absence of systematic data regarding sensory tricks in patients with and without remission no strong conclusions can be drawn.

Although data was only available from a subset of reported remission cases (163/ 414), the majority of patients relapsed (64%). This is unsurprising, as further progression of dystonic pathology, particularly within the first years, would be associated with a failure of compensatory mechanisms to prevent the expression of abnormal movements. This would in turn lead to clinical worsening or even re-emergence of dystonic symptoms. The fact that relapse typically occurred within a few years after the onset of remission further highlights the fragile equilibrium between the factors associated with symptom compensation and a progression of dystonic pathology. Although, relapse occurrence appeared to be less common in CD (57.8%) than in generalized dystonia (100% relapse rate), we do note that this might be due to an underestimation bias. Indeed, relapse was not systematically addressed in the majority of studies and the average follow-up period was relatively brief in CD, as compared to other dystonic phenotypes, for example BSP/Meige syndrome.

The lack of systematic studies in the clinical phenomenon of dystonic remission highlights several, still unresolved questions. First of all, the very definition of remission in the context of dystonia remains unclear. In the medical literature, the term remission (from the latin *remittere, "to send back"*) refers to a state of absence of disease activity in a formerly affected patient (42,43)(Oxford dictionary, 2018; Miller-Keane Encyclopedia and Dictionary of Medicine, 2003). Accordingly, we here used the terms of *complete* and *partial* remission to indicate either absence or improvement of dystonic symptoms and signs respectively. However, among the studies we reviewed, only a quarter provided definitions of remission, whereby in most cases these definitions differed. This heterogeneity also reflects the overall lack of consensus of remission in neurological disorders (44–46)(Havrdova, 2010, Mao, 2015, Fisher, 2017), also including movement disorders (47)(Black, 2016). Based on our extensive review and our critical analysis of the data we suggest the following remission criteria for dystonia. First, we define the *degree of remission* as complete, in the absence of any dystonic symptoms as documented both by objective clinical measures (e.g. clinical observation, scale-based evaluation) and by subjective patient report. We recommend the term of partial remission to be given to cases with incomplete resolution of symptoms according to clinical evaluation alone. Indeed, patient judgements might differ from clinical observation (48)(van Vugt, 2014), particularly with

regard to dystonic severity and might be influenced from other factors, as for example presence of pain or neuropsychiatric comorbidities as depression (49)(Skogseid, 2007). It is, therefore, crucial that the term partial remission relies on clinical evaluation alone. In addition, and given the common fluctuation of dystonic symptoms, we recommend the strict arbitrary criterion of a minimum 50% improvement, as assessed through a phenotype-specific clinician-based dystonic scale in order to document partial remission. Second, we suggest a distinction with regard to the *onset of remission*. We recommend the usage of the term *spontaneous remission* for cases, where resolution or improvement of dystonic symptoms occurs in the absence of previous pharmacological or surgical (e.g. deep brain stimulation) treatments. All other cases, where remission occurred following a treatment intervention, would fall within the *post-treatment* remission group. Indeed, the suggestion that the application of certain treatments in dystonia might potentially lead to long-term benefits due to specific disease-modifying properties has been advanced before (Giladi, 2000; Cheung, 2013) (11,50). Crucially, for patients of the *post-treatment remission* group dystonic symptom improvement would continue to occur in the absence of ongoing treatment. Here, therefore, the introduction of *remission duration* is important. Given the extended temporal effects of certain treatments (e.g. botulinum toxin injections might lead to long-term responses of over 2 years in some patients (11)(Giladi, 2000)), we recommend that for remissions of the *post-treatment* group, any previous intervention should have occurred at least 12 months prior to current clinical evaluation. This period is clearly long enough to allow for remaining pharmacological or other effects of medical interventions to resolve (51,52)(Marsh, 2014, Dressler, 2015). Conversely, for the *spontaneous remission* group, we suggest that a remission duration of at least 6 months is sufficient to document symptom improvement.

Our approach has several limitations. First, our systematic literature review revealed 31 suitable studies comprising data for 2551 dystonia patients. However, and despite this relatively large number, we could not identify robust datasets on other forms of dystonia, as for example focal hand or monogenetic forms of dystonia. Similarly, we could not collect any data on remission rates in tremulous vs. non-tremulous dystonia, particularly CD. As our results appear to be phenotype-specific, little can be, therefore, inferred for these different forms of dystonia. Second, although we did not include studies reporting acquired forms of dystonia or patients with clinical remission under ongoing medical treatments, some papers we included provided limited clinical information. Hence, we cannot completely rule out the possibility that some of cases we analysed, were not in fact referring to patients with acquires causes of dystonia or patients were not experiencing symptom improvement due to on-going medical treatment. However, the number of these patients would be comparatively small to our overall sample, as we actively excluded all cases were this was clearly stated. Finally, we were surprised that many of the studies we identified had been conducted before consensus definitions of dystonia were reached (15,17,20,21,53–56)(Whiles, 1940, Patterson and Little, 1943, Paterson, 1945, Herz und Glaser, 1949, Meares, 1971, Meares, 1971, Tibbetts, 1971, Shaw, 1972, Marsden, 1974), and surprisingly we could identify no study on dystonic remission after the movement disorders society

consensus criteria statement of 2013 (1)(Albanese, 2013). Given the difficulties in distinguishing organic from functional dystonia in many cases, we believe that some of the patients reported here could have had a functional etiology. However, compared to other functional syndromes, patients with functional cervical dystonia are relatively rare.

To conclude, we here assessed the prevalence and clinical characteristics of remission in isolated sporadic dystonia. We show that remission was most prevalent in CD (11.8%), but was also reported for BSP/ Meige (5.8%) and generalized dystonia. For CD, patients with remission were characterized by younger age at onset compared to patients without remission and there was no influence of disease duration or gender. Remission typically occurred within the first 5 years of the disorder, but the majority of patients relapsed. In the absence of a uniform concept of remission in dystonia, we provide a list of operational definition criteria based on the *degree*, *onset* and *duration* of dystonic remission (also summarized in table 3). We hope, that our work here will advance the characterization and documentation of dystonic remission cases in the future. This may in turn provide important insights into the clinical characteristics and further prognostic factors related to this less common but important clinical phenomenon.

References

1.   Albanese A, Bhatia K, Bressman SB, DeLong MR, Fahn S, Fung VSC, et al. Phenomenology and classification of dystonia: A consensus update: Dystonia: Phenomenology and classification. Movement Disorders. 2013 Jun 15;28(7):863–73.

2.   Fung VSC, Jinnah HA, Bhatia K, Vidailhet M. Assessment of patients with isolated or combined dystonia: an update on dystonia syndromes. Mov Disord. 2013 Jun 15;28(7):889–98.

3.   Kojovic M, Pareés I, Kassavetis P, Palomar FJ, Mir P, Teo JT, et al. Secondary and primary dystonia: pathophysiological differences. Brain. 2013 Jul;136(7):2038–49.

4.   Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994;117(4):859–76.

5.   Lohmann K, Klein C. Update on the Genetics of Dystonia. Curr Neurol Neurosci Rep. 2017;17(3):26.

6.   Defazio G, Berardelli A, Abbruzzese G, Coviello V, Carella F, De Berardinis MT, et al. Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group. J Neurol Neurosurg Psychiatry. 1999 Nov;67(5):613–9.

7.   Martino D, Berardelli A, Abbruzzese G, Bentivoglio AR, Esposito M, Fabbrini G, et al. Age at onset and symptom spread in primary adult-onset blepharospasm and cervical dystonia. Mov Disord. 2012 Sep 15;27(11):1447–50.

8.   LeDoux MS, Vemula SR, Xiao J, Thompson MM, Perlmutter JS, Wright LJ, et al. Clinical and genetic features of cervical dystonia in a large multicenter cohort. Neurol Genet. 2016 Jun;2(3):e69.

9.   Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097.

10.   Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. In: Version 5.1.0. The Cochrane Collaboration; 2011.

11.   Giladi N, Meer J, Kidan H, Honigman S. Long-term remission of idiopathic cervical dystonia after treatment with botulinum toxin. Eur Neurol. 2000;44(3):144–6.

12.   Friedman A, Fahn S. Spontaneous remissions in spasmodic torticollis. Neurology. 1986 Mar;36(3):398–400.

13.   Pal PK, Samii A, Schulzer M, Mak E, Tsui JK. Head tremor in cervical dystonia. Can J Neurol Sci. 2000 May;27(2):137–42.

14.   Jahanshahi M, Marion MH, Marsden CD. Natural history of adult-onset idiopathic torticollis. Arch Neurol. 1990 May;47(5):548–52.

15.   Meares R. Features which distinguish groups of spasmodic torticollis. J Psychosom Res. 1971 Mar;15(1):1–11.

16.   Koukouni V, Martino D, Arabia G, Quinn NP, Bhatia KP. The entity of young onset primary

cervical dystonia. Mov Disord. 2007 Apr 30;22(6):843–7.

17.   Marsden CD, Harrison MJ. Idiopathic torsion dystonia (dystonia musculorum deformans). A review of forty-two patients. Brain. 1974 Dec;97(4):793–810.

18.   Bradley EA, Hodge DO, Bartley GB. Benign essential blepharospasm among residents of Olmsted County, Minnesota, 1976 to 1995: an epidemiologic study. Ophthal Plast Reconstr Surg. 2003 May;19(3):177–81.

19.   Lowenstein DH, Aminoff MJ. The clinical course of spasmodic torticollis. Neurology. 1988 Apr;38(4):530–2.

20.   Paterson M. SPASMODIC TORTICOLLIS RESULTS OF PSYCHOTHERAPY IN 21 CASES. The Lancet. 246(6375):556–9.

21.   HERZ E, GLASER GH. Spasmodic torticollis; clinical evaluation. Arch Neurol Psychiatry. 1949 Mar;61(3):227–39.

22.   Matthews WB, Beasley P, Parry-Jones W, Garland G. Spasmodic torticollis: a combined clinical study. J Neurol Neurosurg Psychiatry. 1978 Jun;41(6):485–92.

23.   Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord. 1991;6(2):119–26.

24.   Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):767–72.

25.   Frucht SJ, Fahn S, Greene PE, O'Brien C, Gelb M, Truong DD, et al. The natural history of embouchure dystonia. Mov Disord. 2001 Sep;16(5):899–906.

26.   Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord. 2012 Dec;27(14):1789–96.

27.   Williams L, McGovern E, Kimmich O, Molloy A, Beiser I, Butler JS, et al. Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland. Eur J Neurol. 2017;24(1):73–81.

28.   Defazio G, Esposito M, Abbruzzese G, Scaglione CL, Fabbrini G, Ferrazzano G, et al. The Italian Dystonia Registry: rationale, design and preliminary findings. Neurol Sci. 2017 May;38(5):819–25.

29.   Norris SA, Jinnah HA, Espay AJ, Klein C, Brüggemann N, Barbano RL, et al. Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord. 2016;31(12):1874–82.

30.   Kroneberg D, Plettig P, Schneider G-H, Kühn AA. Motor Cortical Plasticity Relates to Symptom Severity and Clinical Benefit From Deep Brain Stimulation in Cervical Dystonia. Neuromodulation. 2017 Sep 29;

31.   Meunier S, Garnero L, Ducorps A, Mazières L, Lehéricy S, Tézenas Du Montcel S, et al. Human brain mapping in dystonia reveals both endophenotypic traits and adaptive reorganization: Endophenotype in Dystonia. Annals of Neurology. 2001 Oct;50(4):521–7.

32.   Berman BD, Pollard RT, Shelton E, Karki R, Smith-Jones PM, Miao Y. GABAA Receptor

Availability Changes Underlie Symptoms in Isolated Cervical Dystonia. Front Neurol. 2018;9:188.

33.   Sadnicka A, Hoffland BS, Bhatia KP, van de Warrenburg BP, Edwards MJ. The cerebellum in dystonia - help or hindrance? Clin Neurophysiol. 2012 Jan;123(1):65–70.

34.   Draganski B, Schneider SA, Fiorio M, Klöppel S, Gambarin M, Tinazzi M, et al. Genotype–phenotype interactions in primary dystonias revealed by differential changes in brain structure. NeuroImage. 2009 Oct;47(4):1141–7.

35.   Abbruzzese G, Berardelli A, Girlanda P, Marchese R, Martino D, Morgante F, et al. Long-term assessment of the risk of spread in primary late-onset focal dystonia. J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):392–6.

36.   Avanzino L, Tinazzi M, Ionta S, Fiorio M. Sensory-motor integration in focal dystonia. Neuropsychologia. 2015 Dec;79:288–300.

37.   Ganos C, Ferrè ER, Marotta A, Kassavetis P, Rothwell J, Bhatia KP, et al. Cortical inhibitory function in cervical dystonia. Clin Neurophysiol. 2017 Dec 1;

38.   Skinner HB, Barrack RL, Cook SD. Age-related decline in proprioception. Clin Orthop Relat Res. 1984 Apr;(184):208–11.

39.   Ramos VFML, Esquenazi A, Villegas MAF, Wu T, Hallett M. Temporal discrimination threshold with healthy aging. Neurobiol Aging. 2016;43:174–9.

40.   Ingemanson ML, Rowe JB, Chan V, Wolbrecht ET, Cramer SC, Reinkensmeyer DJ. Use of a robotic device to measure age-related decline in finger proprioception. Experimental Brain Research. 2016 Jan;234(1):83–93.

41.   Ramos VFML, Karp BI, Hallett M. Tricks in dystonia: ordering the complexity. Journal of Neurology, Neurosurgery & Psychiatry. 2014 Sep 1;85(9):987–93.

42.   Oxford English Dictionary [Internet]. [cited 2018 Apr 30]. Available from: https://medical-dictionary.thefreedictionary.com/remission

43.   O'Toole M. Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health [Internet]. 7th ed. W. B. Saunders; 2003 [cited 2018 Apr 30]. Available from: https://medical-dictionary.thefreedictionary.com/remission

44.   Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology. 2010 Apr 27;74 Suppl 3:S3-7.

45.   Mao Z, Hu X, Lu Z, Hackett ML. Prognostic factors of remission in myasthenia gravis after thymectomy. European Journal of Cardio-Thoracic Surgery. 2015 Jul;48(1):18–24.

46.   Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. How long for epilepsy remission in the ILAE definition? Epilepsia. 2017;58(8):1486–7.

47.   Black KJ, Black ER, Greene DJ, Schlaggar BL. Provisional Tic Disorder: What to tell parents when their child first starts ticcing. F1000Research. 2016 Apr 18;5:696.

48.   van Vugt FT, Boullet L, Jabusch H-C, Altenmuller E. Musician's dystonia in pianists: long-term evaluation of retraining and other therapies. Parkinsonism Relat Disord. 2014 Jan;20(1):8–12.

49.   Skogseid IM, Malt UF, Røislien J, Kerty E. Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol. 2007 Oct;14(10):1129–37.

50.   Cheung T, Zhang C, Rudolph J, Alterman RL, Tagliati M. Sustained relief of generalized dystonia despite prolonged interruption of deep brain stimulation: Relief of Dystonia Despite Dbs Interruption. Movement Disorders. 2013 Sep;28(10):1431–4.

51.   Marsh WA, Monroe DM, Brin MF, Gallagher CJ. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurology [Internet]. 2014 Dec [cited 2018 Aug 13];14(1). Available from: http://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-14-91

52.   Dressler D, Tacik P, Saberi FA. Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm (Vienna). 2015 Feb;122(2):297–300.

53.   Whiles WH. Treatment of Spasmodic Torticollis by Psychotherapy. Br Med J. 1940 Jun 15;1(4145):969–71.

54.   Patterson R, Little S. Spasmodic torticollis. J Nerv Ment Dis. 1943 Dec;98(6):571–99.

55.   Meares R. Natural history of spasmodic torticollis, and effect of surgery. Lancet. 1971 Jul 17;2(7716):149–50.

56.   Shaw KM, Hunter KR, Stern GM. Medical treatment of spasmodic torticollis. Lancet. 1972 Jun 24;1(7765):1399.

Tables

Table 1. Demographic data of the patient cohort.

Table 2. Descriptive data of patients with remission in dystonia.

Table 3. List of suggested operational definition criteria for remission.

Figures

Figure 1. Flow diagram of the systematic review (according to (9)).

Figure 2. Forest plot of the effect sizes from the studies comparing patients with and without remission in cervical dystonia. Horizontal lines represent 95% confidence intervals. The area of squares is proportional to the studies' sample size. A: Age at disease onset, B: disease duration.